Rhumbline Advisers Eye Point Pharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 76,833 shares of EYPT stock, worth $613,127. This represents 0.0% of its overall portfolio holdings.
Number of Shares
76,833
Previous 57,936
32.62%
Holding current value
$613,127
Previous $1.2 Million
44.19%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding EYPT
# of Institutions
163Shares Held
58.2MCall Options Held
224KPut Options Held
1.41M-
Cormorant Asset Management, LP Boston, MA8.33MShares$66.4 Million5.57% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.18MShares$41.3 Million1.88% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$30 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.65MShares$29.1 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.59MShares$28.7 Million0.06% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $272M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...